首页 | 本学科首页   官方微博 | 高级检索  
检索        

糖尿病开展胰岛素泵连续皮下输注的临床意义
引用本文:陈俏蓉.糖尿病开展胰岛素泵连续皮下输注的临床意义[J].中国医药科学,2014(13):208-211,213.
作者姓名:陈俏蓉
作者单位:广东省阳东县人民医院;
摘    要:目的:探讨2型糖尿病患者采取胰岛素泵连续皮下输注(CSⅡ)与多次胰岛素皮下注射(MSⅡ)对血糖控制的临床疗效差异,并为该病治疗积累经验。方法选取我院内分泌科于2010年3月~2013年9月收治的78例2型糖尿病患者,利用随机数字表法进行分组,分别设为研究组和对照组,每组各39例。其中研究组开展CSⅡ治疗,对照组开展MSⅡ治疗。记录两组患者在治疗前后空腹血糖(FBG)、餐后2h血糖(2hBG)、糖化血红蛋白(HbA1C)及胰岛素用量、不良反应发生率。结果治疗后第4周末,研究组FBG、2hBG值均低于对照组(P<0.05);两组HbA1C值差异无统计学差异(P>0.05)。研究组血糖达标时间短于对照组(P<0.05),胰岛素用量少于对照组(P<0.05)。研究组低血糖和黎明现象发生率均低于对照组(P<0.05)。结论2型糖尿病患者开展胰岛素泵连续皮下输注相较于多次胰岛素皮下注射,血糖控制效果更佳,胰岛素剂量使用更少,不良反应发生率更低,取得较为满意的临床疗效。

关 键 词:2型糖尿病  胰岛素泵  皮下注射  控制血糖  不良反应

Clinical significance of continuous subcutaneous insulin infusion for diabetes
CHEN Qiaorong.Clinical significance of continuous subcutaneous insulin infusion for diabetes[J].China Medicine and Pharmacy,2014(13):208-211,213.
Authors:CHEN Qiaorong
Institution:CHEN Qiaorong ( Yangdong People's Hospital, Guangdong, Yangdong 529900, China)
Abstract:Objective To explore the differences of clinical curative effect of continuous subcutaneous insulin infusion (CSII) and multiple subcutaneous insulin injection (MSII) on blood sugar control for patients with diabetes type 2 and to accumulate experience for the treatment of the disease.Methods78 patients with diabetes type 2 who were admitted to the department of endocrinology in our hospital from March 2010 to September 2013 were selected. They were allocated to a research group and a control group according to random number table, with 39 patients in each group. The research group received CSII and the control group received MSII. FBG, 2hBG, HbA1C, insulin dosage and incidence of adverse events before and after the treatment in the two groups were recorded.ResultsAt the end of the fourth treatment week, FBG and 2hBG in the research group were both lower than those in the control group (P〈0.05); the difference of HbA1C between the two groups were not statistically significant (P〉0.05). Recovery time of blood sugar in the research group was shorter than that in the control group (P〈0.05), and the insulin dosage was less than that in the control group (P〈0.05). Incidence of hypoglycemia and dawn phenomenon were both lower than those in the control group (P〈0.05). Conclusion Compared with MSII, CSII for patients with diabetes type 2 has a better effect of blood sugar control, less insulin dosage, a low incidence of adverse events and a satisfactory clinical effect.
Keywords:Diabetes type 2  Insulin pump  Subcutaneous infusion  Blood sugar control  Adverse events
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号